• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

    6/3/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email

    PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day.

    A webcast of the presentation will be available here beginning at 2:00 pm ET on Tuesday, June 10, 2025 and will be posted on the Investors section of the Company's website.

    About Krystal Biotech, Inc.

    Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved by the FDA and EMA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).

    CONTACT

    Investors and Media:                                                                                        

    Stéphane Paquette

    Krystal Biotech

    [email protected]                                                                                   



    Primary Logo

    Get the next $KRYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    4/18/2023$102.00Buy
    Stifel
    2/28/2023$79.00 → $124.00Neutral → Buy
    Goldman
    More analyst ratings

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

      Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to 20/25 at 8 months PITTSBURGH, June 24, 2025 (GLOBE NEWSWIRE) --  Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the first patient has been dosed in its Phase 3 clinical trial ("IOLITE"), an intra-patient, double-blind, multicenter, placebo-controlled study with crossover design evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epider

      6/24/25 7:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      PITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 2:00 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 2:00 pm ET on Tuesday, June 10, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biot

      6/3/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

      PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology co

      5/7/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

      For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

      5/19/23 1:48:20 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, R&D Krishnan Suma sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,463,711 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      3/13/25 6:06:28 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Krishnan Krish S sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,533,056 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      3/13/25 6:04:23 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Romano Kathryn covered exercise/tax liability with 8,054 shares, sold $131,415 worth of shares (750 units at $175.22) and converted options into 12,500 shares, increasing direct ownership by 24% to 19,318 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      2/28/25 7:01:45 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    SEC Filings

    See more
    • Krystal Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      6/2/25 5:12:19 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      5/19/25 5:06:24 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      5/6/25 8:09:31 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care